| Dr Jason Michael Durbin, DO | |
|
9398 Ridgetop Blvd Nw, Silverdale, WA 98383-8505 | |
| (360) 782-3222 | |
| (360) 782-3244 |
| Full Name | Dr Jason Michael Durbin |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 22 Years |
| Location | 9398 Ridgetop Blvd Nw, Silverdale, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124098173 | NPI | - | NPPES |
| 2017817 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 2003018910 (Missouri) | Secondary |
| 208800000X | Urology | OP60272190 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harrison Medical Center | Bremerton, WA | Hospital |
| Olympic Medical Center | Port angeles, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Medical Group | 0547173866 | 1115 |
News Archive
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).
Families with children suffering from brain tumours caused by an uncommon genetic disorder known as Tuberous Sclerosis Complex (TSC) have new hope with Health Canada's recent conditional approval of a new therapeutic use for the drug Afinitor (everolimus). Afinitor is the first drug therapy approved in Canada for the treatment of brain tumours caused by TSC in patients three years of age and older.
"Such claims are raised regularly by certain groups but have not been found to be justified on either technical or commercial grounds."
An examination of Seattle's Group Health raises questions about the role of health co-ops in insurance reform. Seattle Weekly reports: "Two weeks ago, as the national debate over health care began to fixate on cooperatives like Seattle's Group Health as a possible model for reform, Eugene and Yukiko Gatlin filed for bankruptcy protection.
› Verified 4 days ago
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).
Families with children suffering from brain tumours caused by an uncommon genetic disorder known as Tuberous Sclerosis Complex (TSC) have new hope with Health Canada's recent conditional approval of a new therapeutic use for the drug Afinitor (everolimus). Afinitor is the first drug therapy approved in Canada for the treatment of brain tumours caused by TSC in patients three years of age and older.
"Such claims are raised regularly by certain groups but have not been found to be justified on either technical or commercial grounds."
An examination of Seattle's Group Health raises questions about the role of health co-ops in insurance reform. Seattle Weekly reports: "Two weeks ago, as the national debate over health care began to fixate on cooperatives like Seattle's Group Health as a possible model for reform, Eugene and Yukiko Gatlin filed for bankruptcy protection.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Michael Durbin, DO 9621 Ridgetop Blvd Nw, Silverdale, WA 98383-8502 Ph: (360) 782-3600 | Dr Jason Michael Durbin, DO 9398 Ridgetop Blvd Nw, Silverdale, WA 98383-8505 Ph: (360) 782-3222 |
News Archive
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).
Families with children suffering from brain tumours caused by an uncommon genetic disorder known as Tuberous Sclerosis Complex (TSC) have new hope with Health Canada's recent conditional approval of a new therapeutic use for the drug Afinitor (everolimus). Afinitor is the first drug therapy approved in Canada for the treatment of brain tumours caused by TSC in patients three years of age and older.
"Such claims are raised regularly by certain groups but have not been found to be justified on either technical or commercial grounds."
An examination of Seattle's Group Health raises questions about the role of health co-ops in insurance reform. Seattle Weekly reports: "Two weeks ago, as the national debate over health care began to fixate on cooperatives like Seattle's Group Health as a possible model for reform, Eugene and Yukiko Gatlin filed for bankruptcy protection.
› Verified 4 days ago
Theodore Eugene Johnsrude, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3200 Fax: 360-782-3245 | |
Dr. Marc A Mitchell, DO Urology Medicare: Accepting Medicare Assignments Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3222 Fax: 360-782-3245 | |
Amy Li, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3200 Fax: 360-782-3244 | |
Randall James Moeller, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3200 Fax: 360-782-3244 | |
Todd Jeffrey Garvin, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 9398 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-782-3222 Fax: 360-782-3245 | |
Marc E. Lee, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 10452 Silverdale Way Nw, Silverdale, WA 98383 Phone: 360-307-7300 |